Domino's Pizza Master Issuer LLC 2011-1 $1.625 Billion Notes Assigned Preliminary Ratings Aug 11

  • ID: 1857844
  • August 2011
  • Standard & Poors
1 of 3

OVERVIEW Domino's Pizza Master Issuer LLC's issuance is an ABS transaction backed by franchise royalty and license payments, franchisor's intellectual property, and profit from distribution arrangements. We assigned our preliminary ratings to the class A notes. The preliminary ratings reflect our view of the transaction's projected cash flows supporting the notes, the strength of the "Domino's" brand, the likelihood for the brand to survive a bankruptcy of Domino's Pizza Inc., and the brand's resulting capacity to continue to generate sufficient cash flows from business operations, and the transaction's legal and payment structures, among other factors. NEW YORK (Standard & Poor's) Aug. 4, 2011--Standard & Poor's Ratings Services today assigned its preliminary ratings to Domino's Pizza Master Issuer LLC's $1.625 billion...

Companies mentioned in this report are: Dominos Pizza Master Issuer LLC
Action: Preliminary Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Dominos Pizza Master Issuer LLC

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.